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Abstract
Nitrofurantoin is one of the most common drugs implicated in drug-induced pulmonary toxicities, the manifestations of which range 
from dose-independent acute self-limiting reactions to chronic dose-dependent pathologies. The severity of these pulmonary adver-
se effects may range from trivial hypersensitivity reactions to extensive and irreversible lung fibrosis leading to respiratory failure 
and death. Symptomatic and supportive treatment in addition to discontinuation of the drug usually suffices for the management of 
mild reactions. Corticosteroids have been traditionally used to relieve the symptoms and hasten the resolution of pulmonary lesions 
in case of severe toxicities. However conclusive evidence in the form of controlled studies in favor of this routine use is lacking. 
We report a case of an elderly lady who presented to us in respiratory failure due to nitrofurantoin induced chronic lung disease. 
The patient’s symptoms and blood gas abnormalities resolved spontaneously over the course of 6 months after stopping the drug. 
Radiological lesions including those suggestive of apparently permanent fibrosis also resolved during this time. Corticosteroids, 
inhalational or systemic, were not used. Spontaneous normalization of clinico-radiological features in nitrofurantoin induced chronic 
lung disease presenting with respiratory failure has rarely been reported previously. The related literature is also reviewed. 
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Introduction
Nitrofurantoin is one of the most common 
antimicrobials used for prophylaxis as well as 
treatment of urinary tract infections (UTIs) [1]. 
The Infectious Diseases Society of America and 
the European Society for Microbiology and Infec-
tious Diseases recommend nitrofurantoin as one 
of the first line antibiotics in uncomplicated UTIs, 
given the low cost of therapy, efficacy as well as 
its positive impact on antimicrobial resistance 
patterns [1]. However, nitrofurantoin is also one of 
the most common drugs to be reported for a varie-
ty of pulmonary, hepatic and peripheral nervous 
system adverse effects [2–4]. The spectrum of 
pulmonary toxicities ranges from acute hyper-
sensitivity reactions to chronic dose-dependent 
pathologies like chronic interstitial pneumoni-
tis, fibrosis and organizing pneumonia [2–4]. In 
view of these possible side effects and available 
alternative medicines, the American Geriatrics 
Society in a 2015 update listed nitrofurantoin as 
a “potentially inappropriate medication” for pro-
longed use in adults 65 years of age and older [4]. 
Mild pulmonary reactions due to nitrofuran-
toin usually resolve spontaneously after the drug 
is discontinued [2, 3]. The literature on the mana-
gement of nitrofurantoin-induced severe chronic 
pulmonary toxicities is meager. Corticosteroids, 
in addition to supportive therapy, are often used 
in these patients, even though the evidence in 
support of such routine application in the form 
of controlled trials is lacking [2, 3]. We report 
a case of an elderly lady who presented to us with 
respiratory failure as a result of severe pulmona-
ry toxicity due to prolonged nitrofurantoin use. 
Advances in Respiratory Medicine 2017, vol. 85, no. 6, pages 333–338 
334 www.journals.viamedica.pl
Figure 1. A — chest radiograph at presentation showing consolidations and reticulonodular pattern in bilateral mid and lower zones; B — chest 
radiograph after 6 months of presentation showing near-normalization of radiological abnormalities
After the drug was stopped, the patient improved 
gradually without the use of inhaled or systemic 
corticosteroids. 
Case report 
An 85-year-old never-smoker, HIV-negative 
lady was referred to our hospital for evaluation of 
her progressive respiratory symptoms including 
non-productive cough and breathlessness on exer-
tion, for the preceding one month. The patient did 
not report fever, chest pain or wheeze. There was 
no history of exposure to fumes or contact with 
domestic pets. Her past history was unremarka-
ble except for recurrent urinary tract infections 
for which she was taking regular nitrofurantoin 
prophylaxis (50 mg once daily) for the preceding 
three years.
On clinical examination the patient was in 
respiratory distress. She had tachycardia (pulse 
rate of 104/minute) and tachypnea (respiratory 
rate of 28/minute). The woman was hypoxemic 
with an SpO2 of 78% while breathing room air. 
Chest examination revealed symmetrical dia-
phragmatic excursion with bilateral fine rales on 
inspiration. The rest of the systemic examination 
was unremarkable.
Blood counts, hemoglobin, kidney/liver func-
tion tests and routine urine analysis did not reveal 
any abnormality. Arterial blood gas (ABG) anal-
ysis confirmed hypoxemia with PaO2 of 51 mm 
Hg while breathing room air. Chest radiograph at 
the time of presentation (Fig. 1A) demonstrated 
bilateral peripheral reticulonodular opacities and 
consolidations in mid and lower zones with rela-
tive sparing of upper zones. High resolution com-
puted tomography (HRCT) of the thorax (Fig. 2) 
revealed bilateral, patchy, sub-pleural and 
peribronchial consolidations, reticular opacities 
and areas of mosaic lung attenuation along with 
traction bronchiectasis and architectural distor-
tion. Multiple sputum samples and a bronchoal-
veolar lavage (BAL) were negative on gram stain, 
Ziehl-Neelsen stain for acid fast bacilli and KOH 
mounts on microscopy. Sputum and BAL cultures 
for aerobic bacteria, fungi and Mycobacterium 
tuberculosis were also negative. Pulmonary func-
tion test (PFT) revealed a restrictive pattern with 
reduced forced vital capacity (FVC) (55% of the 
predicted value) and normal FEV1/FVC (79%). 
Diffusion capacity for carbon monoxide (DLCO) 
was also reduced (59% of the predicted value). Se-
rology for antinuclear, anti-double stranded DNA, 
anti Scl 70, anti-citrullinated cyclic polypeptide 
and antineutrophil cytoplasmic antibodies (both 
perinuclear and cytoplasmic) was negative. 
In view of a history of exposure to a drug 
known to cause pulmonary toxicity, temporal 
association of drug exposure with the clinical 
condition, typical clinico-radiological presen-
tation and a negative workup for infectious and 
connective tissue diseases, nitrofurantoin was 
presumed to be the causative agent for the dis-
ease. The patient’s score on the Naranjo Adverse 
Drug Reaction Probability Scale [5] was 7, which 
placed the patient in a “probable adverse drug 
reaction” category. 
Nitrofurantoin was immediately stopped at 
admission. During her stay at the hospital, the 
patient was given only symptomatic treatment 
with inhaled salbutamol along with supplemen-
tal oxygen. Neither corticosteroids, inhalational 
or systemic, nor antibiotics were used. The 
clinical condition of the patient gradually im-
A B
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Figure 2. HRCT at presentation showing bilateral sub-pleural reticular opacities, patches of subpleural and peribronchial consolidation, mosaic lung 
attenuation and architectural distortion  
proved during her stay at the hospital. She was 
discharged with continuous oxygen therapy at 
home and advised regarding strict avoidance of 
nitrofurantoin and regular outpatient follow up. 
The patient showed further gradual improve-
ment at home. Over a course of six months, she 
became asymptomatic. Her respiratory failure 
also resolved, with oxygen saturation and PaO2 
improving to 97% and 77 mm Hg, respectively, 
while breathing room air. Lung function tests 
including spirometry and diffusion capacity 
were also normal for her age, sex and height at 
the end of 6 months. Chest radiograph (Fig. 1B) 
and HRCT of the thorax (Fig. 3) repeated after 6 
months revealed nearly complete resolution of 
radiological abnormalities.
Discussion 
Nitrofurantoin-induced lung disease (NILD) 
was first reported by Fisk in 1957 who described 
an acute self-limiting reaction to nitrofurantoin 
characterized by fever, dyspnea, cough, chest 
pain, rash, arthralgia, tachycardia and tachy-
pnea [6]. Chronic NILD is less common than the 
acute form, and can appear months to even years 
after initiation of treatment [2, 3]. It most com-
monly occurs in older women due to the higher 
prevalence of UTIs in this age group. The usual 
presentation is gradual onset of cough, progres-
sive dyspnea, myalgia, weight loss and fatigue. 
Clinical findings include bilateral inspiratory fine 
rales and clubbing. Chest radiograph commonly 
reveals bilateral interstitial infiltrates predomi-
nantly in the lower zones. Pulmonary function 
test (PFT) may reveal a restrictive pattern with 
reduced diffusion capacity. High resolution com-
puted tomography (HRCT) scan findings include 
ground-glass attenuation, inter- and intra-lobular 
septal thickening, traction bronchiectasis, honey-
combing and organizing pneumonia [2, 3]. Our 
patient therefore presented with a chronic NILD 
with classical clinico-radiological features. Lung 
biopsy was not done. However, radiological pic-
ture was suggestive of interstitial inflammation 
(reticular opacities), fibrosis (architechtural dis-
tortion and traction bronchiectasis), organizing 
pneumonia (peripheral, subpleural and peribron-
chial consolidations) as well as a probable small 
airway involvement (mosaic attenuation). 
We searched PubMed for cases of nitrofuran-
toin-induced lung adverse lung reactions leading 
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Figure 3. HRCT of thorax after 6 months of presentation showing near-complete resolution of radiological abnormalities
to respiratory failure that resolved spontaneously 
using the key words “NITROFURANTOIN”, 
“LUNG”, “PULMONARY”, “CORTOCOSTE-
ROIDS” and “ILD”. We could find only 4 such 
cases [7–10] published in English since 1953 
(Table 1). All of these patients were females 
and almost all of them had a  complete spon-
taneous normalization of clinico-radiological 
picture. The time of resolution varied between 
3 to 4 months in 3 patients while 1 patient had 
nitrofurantoin-induced respiratory arrest only 
without parenchymal involvement, which re-
solved in a day without the use of corticosteroids 
[7–10]. Histopathology revealed granulomatous 
pneumonitis in the only patient who underwent 
a lung biopsy [9]. Our patient showed complete 
resolution of symptoms, near-normalization of 
blood gas parameters as well as radiological 
changes in 6 months. Surprisingly, radiological 
features suggestive of irreversible fibrosis like 
traction bronchiectasis and architectural distor-
tion also resolved with time. Such resolution of 
apparently permanent fibrosis has been previ-
ously reported [12].
NILD-related mortality is well document-
ed [2, 3, 13]. In our patient careful history and 
prompt drug withdrawal avoided further morbid-
ity as well as an unnecessary lung biopsy. This 
case highlights the need for increased sensitivity 
towards nitrofurantoin-induced lung adverse 
events especially in older adults after prolonged 
use. The patients may require continued surveil-
lance for these toxicities in the form of periodic 
radiographs, pulmonary function tests and arte-
rial blood gas monitoring. 
The role of corticosteroids in severe NILD 
is controversial. It is impossible to conduct con-
trolled studies in these patients to substantiate 
the evidence for or against the routine use of 
steroids. Many NILD patients have succumbed in 
spite of corticosteroid therapy [2, 3, 13]. Even in 
patients already on immunosuppressive therapy, 
fresh nitrofurantoin-related pulmonary adverse 
events including fatal pulmonary hemorrhag-
es have been reported [13]. Regular follow up 
avoided many corticosteroid-related side effects 
in our patient. 
We can conclude through this case and other 
case reports [7–10] that there is at least a subset 
of patients with advanced chronic NILD who will 
show spontaneous resolution of clinico-radiolog-
ical abnormalities after drug withdrawal without 
corticosteroid use. We recommend strict follow 
up with monitoring of lung functions and blood 
gases after drug withdrawal until complete nor-
malization in such patients. 
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